Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2

Clinical CDK4/6 inhibitors are used and tested to treat a variety of cancer types. Here, the authors identify that these drugs work in two ways, a known catalytic role to inhibit kinase activity and a newly discovered noncatalytic role to displace CDK inhibitor p21 from CDK4 but not CDK6 complexes.

Saved in:
Bibliographic Details
Main Authors: Lindsey R. Pack, Leighton H. Daigh, Mingyu Chung, Tobias Meyer
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Q
Online Access:https://doaj.org/article/6d14f142aabc4361a0362428e11c38f1
Tags: Add Tag
No Tags, Be the first to tag this record!